Barclays maintains Becton Dickinson at Underweight, raises price target to $195 from $165
Barclays kept its Underweight rating on Becton Dickinson but raised its price target to $195 from $165, suggesting a 9.4% downside from the Nov 9 close. Recent analyst price targets for the company range from $200 to $241.
How this was made

The 30-second read
Why it matters
The modest target increase may not move the stock significantly, but it signals a slightly more optimistic outlook.
Market read
A small analyst upgrade with limited price impact; relevant for short‑term traders monitoring BDX.
What to watch
Potential upcoming product launches or contract wins not mentioned could change the outlook.
Background
Barclays' analyst note updates its valuation for Becton Dickinson, a leading medical device maker.
Ticker impact
Barclays raised its price target on Becton Dickinson to $195 from $165.
likely pressure as the market prices in the lower target
Analyst target increase is modest and still below the stock's recent close, so traders may see limited upside.
Market effects
Minimal impact on the medical devices sector; only reflects one analyst's view.
U.S. market only; no broader regional effect.
Low; the news is specific to BDX and does not affect global markets.
Counterpoint
Some investors may view the target raise as a sign of confidence and could buy on dips.
Key entities
- AnalystBarclays
Equity research firm providing the price target update.
- CompanyBecton Dickinson
Medical device manufacturer (ticker BDX).



